Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Dato-DXd
Drug: Capecitabine
Drug: Durvalumab
Drug: Pembrolizumab

First Posted Date: 2022-11-29

Last Posted Date: 2024-12-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 1075

Registration Number: NCT05629585

Locations: 🇬🇧
Research Site, Taunton, United Kingdom

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Phase 2

Recruiting

Conditions: Recurrent Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: 5FU
Drug: folinic acid
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Raltitrexed
Drug: Cetuximab
Drug: Bevacizumab
Radiation: Radiation

First Posted Date: 2022-11-28

Last Posted Date: 2024-10-01

Lead Sponsor: Fudan University

Target Recruit Count: 93

Registration Number: NCT05628038

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986360
Drug: Docetaxel
Drug: Nivolumab
Drug: Capecitabine

First Posted Date: 2022-11-22

Last Posted Date: 2024-08-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 220

Registration Number: NCT05625412

Locations: 🇺🇸
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States
🇺🇸
Local Institution - 0019, Los Angeles, California, United States
🇦🇷
Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina

and more 35 locations

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

Phase 2

Recruiting

Conditions: Locally Advanced Rectal Carcinoma
Stage III Rectal Cancer AJCC v8
Stage II Rectal Cancer AJCC v8

Interventions: Drug: Capecitabine
Drug: 5-fluorouracil
Drug: Leucovorin calcium
Drug: Oxaliplatin
Drug: Irinotecan
Radiation: Long Course Chemoradiotherapy
Procedure: Magnetic Resonance Imaging
Procedure: Computed Tomography
Procedure: Sigmoidoscopy
Procedure: biopsy

First Posted Date: 2022-11-09

Last Posted Date: 2024-10-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 312

Registration Number: NCT05610163

Locations: 🇺🇸
Lutheran Hospital - Cancer Centers of Colorado, Golden, Colorado, United States
🇺🇸
Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States
🇺🇸
Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States

and more 632 locations

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Phase 1

Not yet recruiting

Conditions: Gastroesophageal-junction Cancer
Gastric Cancer

Interventions: Drug: IBI315
Drug: Oxaliplatin
Drug: Capecitabine
Drug: TST001
Drug: TQB2450
Drug: Anrotinib

First Posted Date: 2022-11-08

Last Posted Date: 2022-11-08

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 45

Registration Number: NCT05608785

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Phase 1

Recruiting

Conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Interventions: Drug: LBL-007
Drug: Tislelizumab
Drug: Bevacizumab biosimilar
Drug: Capecitabine
Drug: 5-Fluorouracil

First Posted Date: 2022-11-08

Last Posted Date: 2024-10-28

Lead Sponsor: BeiGene

Target Recruit Count: 226

Registration Number: NCT05609370

Locations: 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸
Ut Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
🇨🇳
Nanyang Central Hospital, Nanyang, Henan, China

and more 74 locations

Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Locally Advanced Colorectal Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin
Drug: Bevacizumab
Drug: Pembrolizumab

First Posted Date: 2022-10-19

Last Posted Date: 2022-10-19

Lead Sponsor: Shanghai Changzheng Hospital

Target Recruit Count: 12

Registration Number: NCT05585814

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Phase 3

Active, not recruiting

Conditions: Advanced Upper Gastrointestinal Tract Adenocarcinoma

Interventions: Drug: Domvanalimab
Drug: Fluorouracil
Drug: Zimberelimab
Drug: Capecitabine
Drug: Leucovorin
Drug: Nivolumab
Drug: Oxaliplatin

First Posted Date: 2022-10-05

Last Posted Date: 2024-11-15

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 1040

Registration Number: NCT05568095

Locations: 🇺🇸
UCLA Ronald Reagan Med Ctr, Santa Monica, California, United States
🇺🇸
Smillow Cancer Hosp, New Haven, Connecticut, United States
🇺🇸
Regions Hospital, Saint Louis Park, Minnesota, United States

and more 199 locations